1st Quarter - Report

INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$60,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to Recurrent Respiratory Papillomatosis (RRP), an HPV associated disease; Issues related to the Orphan Drug Act and orphan drug destination; Issues related to the Orphan Drug Tax Credit; Issues related to Accelerated Approval reforms and accelerated approval pathway at FDA; Issues related to CMS IRA implementation and small biotech exemption; Issues related to the Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of pan-coronavirus vaccines and boosters; Issues related to Oncology and HPV cancers and other associated diseases; DNA Medicines Platform Technology awareness

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.